Business Context and Reporting Period
This Form 8-K was filed by Genesis Biopharma, Inc. (noted in metadata as IOVANCE BIOTHERAPEUTICS, INC.) on July 25, 2011, with the report date of July 28, 2011. The filing details the completion of a private placement offering of senior convertible notes and warrants to fund working capital.
Key Financial Metrics and Transaction Details
- Total Offering Size: $5.0 million in 7% senior convertible notes and 5-year warrants.
- Immediate Proceeds: $2.5 million received upon closing of the first tranche.
- Escrowed Amount: $2.5 million held in escrow pending specific milestones.
- Conversion/Exercise Price: $1.25 per share (85% of the trailing 5-day VWAP).
- Shares Underlying Initial Tranche: 2,000,000 shares of Common Stock.
- Transaction Fees: 7% of gross proceeds paid to agents (Canaccord Genuity, Inc. and Cowen and Company, Inc.).
- Placement Warrants: 2% of securities sold issued to agents.
- Note Maturity: November 30, 2011.
Material Changes and Transaction Structure
The company entered into a Securities Purchase Agreement (SPA) with five accredited investors. The offering is structured in two equal tranches:
- Tranche A (Completed): $2.5 million in notes and warrants issued immediately.
- Tranche B (Escrowed): $2.5 million in notes and warrants held in escrow. Release is contingent upon the company signing a worldwide nonexclusive license for U.S. Government-owned tumor infiltrating lymphocyte and T-cell technologies, and a Cooperative Research and Development Agreement for exclusive access to additional technologies, prior to the November 30, 2011 termination date.
If the milestones are not met by the termination date, the escrowed securities return to the company and the funds return to the investors.
Outlook, Risks, and Contingencies
- Registration Rights Penalty: The company must file a registration statement for the underlying shares. Failure to have it declared effective within 90 days (or 120 days if reviewed) results in a penalty of 1.0% of the aggregate purchase price every 30 days until compliance.
- Redemption Feature: The company can force conversion if the common stock trades at 200% of the conversion price ($2.50) for 20 consecutive trading days with a minimum daily volume of 100,000 shares.
- Anti-Dilution Protection: Conversion and exercise prices are subject to adjustment based on subsequent financings.
- Cashless Exercise: Warrants include cashless exercise provisions if shares are not registered.
Investor Verification Checklist
- Verify the status of the U.S. Government license and Cooperative Research and Development Agreement required to release the $2.5 million escrowed funds.
- Confirm the filing status and expected effectiveness date of the registration statement to avoid 1.0% monthly penalties.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific anti-dilution adjustment formulas.
- Assess the company's current cash position relative to the $2.5 million received versus total working capital needs.